Vuong Trieu is a businessperson who founded IgDraSol, Inc. and Oncotelic, Inc. and who has been at the head of 9 different companies. Presently, Dr. Trieu occupies the position of Chairman, President & Chief Executive Officer for Oncotelic Therapeutics, Inc., Chairman, President & Chief Executive Officer for Oncotelic, Inc. (a subsidiary of Oncotelic Therapeutics, Inc.), Chief Executive Officer of Autotelic, Inc., President & Director at Stocosil, Inc., Chief Operating Officer for LipoMedics, Inc. and Chairman for IthenaPharma, Inc.
He is also Member of American Society of Clinical Oncology, Member of American Association for Cancer Research and Member of The Endocrine Society.
In his past career he was Executive Chairman & Chief Executive Officer of Adhera Therapeutics, Inc., Director at Adhera Therapeutics, Inc., Director at Sorrento Therapeutics, Inc., Director-Cardiovascular Biology Program at Parker Hughes Institute, Chief Executive Officer for IgDraSol, Inc. and Pharmacology Director at Abraxis BioScience, Inc.
Vuong Trieu received a doctorate from the University of Oklahoma.